Skip to main content
. 2020 Aug 20;64(9):e00773-20. doi: 10.1128/AAC.00773-20

FIG 1.

FIG 1

HCV clearance reduces the activated phenotype of monocytes. (A) Dynamic changes in the frequencies of monocyte subsets. (B) Percentages of surface expression of activation markers among HIV/HCV-coinfected patients at baseline (BL) and at the end of treatment (ET) and the HIV-monoinfected control group (Ctrl). The Wilcoxon test was used to compare HIV/HCV-coinfected patients at baseline and at the end of treatment. The Mann-Whitney U test was used to compare HIV/HCV-coinfected patients and the HIV-monoinfected patient control group. *, P < 0.05; **, P < 0.001; NS, not significant.